Compare Neurocrine Biosciences Inc (NBIX) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Nvidia Corp — how do they compare? Neurocrine Biosciences Inc trades at $141.09 (market cap $14.60B), while Nvidia Corp trades at $233.71 (market cap $5.73T). The key difference: Nvidia Corp is far larger — about 392.5× Neurocrine Biosciences Inc's market cap, and Nvidia Corp pays a 0.42% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Nvidia Corp for 115 Days on average.
| NBIX | NVDA | |
|---|---|---|
Market Cap | $14.60B | $5.73T |
Volume | 1,075,694 | 81,027,431 |
Sector | Health | Technology |
52-Week High | $185.50 | $239.27 |
52-Week Low | $123.10 | $165.17 |
Typical Hold Time | 23 Days | 115 Days |
Enterprise Value | $14.61B | $5.71T |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $143.47, down 1.4% on the day, with a bearish technical signal but strong fundamentals including a 20.91% net income margin and consistent earnings beats. Recent news highlights pipeline advancements in Prader-Willi syndrome and executive appointments, while analyst consensus remains strongly bullish with a $204.18 price target.
The outlook is positive based on robust profitability and growth initiatives, though risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharma company with a deep pipeline, balanced by near-term technical weakness.
NVIDIA (NVDA) trades at $230.48, down 3.67% on the day, amid a broader tech sell-off. The stock maintains a bullish technical signal with strong moving averages, though oscillators are neutral and RSI levels suggest potential overbought conditions. Fundamentally, the company reported robust revenue of $130.50B in 2025 with a net income margin of 63.66%, and it has consistently beaten earnings expectations in recent quarters. Recent news highlights AI-driven growth prospects but also notes concerns about market saturation and geopolitical impacts on U.S. equities.
The outlook for NVDA remains positive due to its dominant position in AI chips and accelerating revenue growth, with Wall Street consensus pointing to significant upside from the current price. Key risks include heightened competition, peak AI spending cycles, and macroeconomic volatility. The stock presents a compelling opportunity for growth-oriented investors, but requires monitoring of execution risks and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
